11,313 results on '"ALZHEIMER"'
Search Results
2. Neuroprotective role of epigallocatechin-3-gallate, albeginin and melanoxetin in alzheimer's disease
- Author
-
Malik, Arif, Hassan, Mehreen, Waquar, Sulayman, Wasim, Muhammad, Naz, Anam, Awan, Faryal M., Khan, Muhammad T., Khawaja, Ali I., Zaib, Sumera, Iqbal, Jamshed, Zahid, Ayesha, Marvi, Marvi, Iqbal, Javeid, Wang, Heng, and Wei, Dong-Qing more...
- Published
- 2025
- Full Text
- View/download PDF
Catalog
3. Neuroprotective role of mirabegron: Targeting beta-3 adrenergic receptors to alleviate ulcerative colitis-associated cognitive impairment
- Author
-
Nasser, Salma, El-Abhar, Hanan S., El-Maraghy, Nabila, Abdallah, Dalaal M., Wadie, Walaa, and Mansour, Suzan
- Published
- 2025
- Full Text
- View/download PDF
4. The synthetic cannabinoid WIN 55,212-2 attenuates cognitive and motor deficits and reduces amyloid load in 5XFAD Alzheimer mice
- Author
-
Möller, Johanna E.L., Schmitt, Franziska W., Günther, Daniel, Stöver, Alicia, and Bouter, Yvonne
- Published
- 2025
- Full Text
- View/download PDF
5. Gold nanostars functionalized with a D-peptide promote disaggregation and improve detection of amyloid-β fibrils: In vitro and In vivo studies
- Author
-
Donoso-González, Orlando, Jara-Guajardo, Pedro, Cabrera, Pablo, Hengsbach, Rebecca, Noyong, Michael, Aldunate, Rebeca, Sierpe, Rodrigo, Araya, Eyleen, Celis, Freddy, Melo, Francisco, Simon, Ulrich, Yutronic, Nicolás, and Kogan, Marcelo J. more...
- Published
- 2025
- Full Text
- View/download PDF
6. Exploring the impact of APOE ɛ4 on functional connectivity in Alzheimer’s disease across cognitive impairment levels
- Author
-
Dong, Kangli, Liang, Wei, Hou, Ting, Lu, Zhijie, Hao, Yixuan, Li, Chenrui, Qiu, Yue, Kong, Nan, Cheng, Yan, Wen, Yaqi, Ma, Wanyin, Zheng, Wenbin, Guan, Jitian, Lin, Yan, Huang, Kai, Zhang, Lu, Chen, Siya, Ma, Xiangyuan, Wu, Renhua, and Wei, Naili more...
- Published
- 2025
- Full Text
- View/download PDF
7. Neurotoxicity of aluminium chloride and okadaic acid in zebrafish: Unravelling Alzheimer's disease model via learning and memory function evaluation
- Author
-
Raduan, S.Z., Ahmed, Q.U., Rusmili, M.R.A., Sabere, A.S.M., Haris, M.S., Shaikh, M.F., Sulaiman, W.A.W., and Mahmood, M.H.
- Published
- 2025
- Full Text
- View/download PDF
8. Associations between differential connectivity patterns of executive control networks and APOE ɛ4 in the Alzheimer continuum
- Author
-
Han, Ruichen, Zhang, Xue, Chen, Ya, Hou, Xinle, and Bai, Feng
- Published
- 2025
- Full Text
- View/download PDF
9. Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective
- Author
-
Conceição, Mariana, Di Filippo, Leonardo Delello, Duarte, Jonatas Lobato, Beserra, Fernando Pereira, Gremião, Maria Palmira Daflon, and Chorilli, Marlus
- Published
- 2024
- Full Text
- View/download PDF
10. Evaluation of machine learning models for the prediction of Alzheimer's: In search of the best performance
- Author
-
Cabanillas-Carbonell, Michael and Zapata-Paulini, Joselyn
- Published
- 2025
- Full Text
- View/download PDF
11. Conformationally adaptive therapeutic peptides for diseases caused by intrinsically disordered proteins (IDPs). New paradigm for drug discovery: Target the target, not the arrow
- Author
-
Fantini, Jacques, Azzaz, Fodil, Di Scala, Coralie, Aulas, Anaïs, Chahinian, Henri, and Yahi, Nouara
- Published
- 2025
- Full Text
- View/download PDF
12. A novel 14mer peptide, T14, is associated with age-dependent behaviour in female mice
- Author
-
Hasan, Sibah, Khan, Adam Mohammed, Garcia-Ratés, Sara, Murphy, Robin A., and Greenfield, Susan A.
- Published
- 2025
- Full Text
- View/download PDF
13. Interactions of memantine and rivastigmine with graphene oxide nanocarrier and beta-amyloid protein using molecular docking and in-silico methods
- Author
-
Davoudi, Fateme, Shadjou, Nasrin, and Darroudi, Mahdieh
- Published
- 2024
- Full Text
- View/download PDF
14. A comprehensive review of advanced focused ultrasound (FUS) microbubbles-mediated treatment of Alzheimer's disease
- Author
-
Rouhi, Nadiyeh, Chakeri, Zahra, Ghorbani Nejad, Behnam, Rahimzadegan, Milad, Rafi Khezri, Mohammad, Kamali, Hossein, and Nosrati, Rahim
- Published
- 2024
- Full Text
- View/download PDF
15. Intra-uterus phthalate exposure, ROS formation and altered mitochondrial D-loop methylation pattern at birth as potential triggers and markers of Alzheimer’s disease
- Author
-
Colbeich da Silveira, Eduarda and Chies, José Artur Bogo
- Published
- 2024
- Full Text
- View/download PDF
16. Investigation of docking, antioxidant, and anti-alzheimer activities of newly schiff bases containing aryl sulfonate group
- Author
-
Çınar, Ercan
- Published
- 2025
- Full Text
- View/download PDF
17. Artificial sharp-wave-ripples to support memory and counter neurodegeneration
- Author
-
Keil, Julian, Kiiski, Hanni, Doherty, Liam, Hernandez-Urbina, Victor, Vassiliou, Chrystalleni, Dean, Camin, Müschenich, Markus, and Bahmani, Hamed
- Published
- 2024
- Full Text
- View/download PDF
18. In silico designing of multiepitope-based-peptide (MBP) vaccine against MAPK protein express for Alzheimer's disease in Zebrafish
- Author
-
Arfat, Yasir, Zafar, Imran, Sehgal, Sheikh Arslan, Ayaz, Mazhar, Sajid, Muhammad, Khan, Jamal Muhammad, Ahsan, Muhammad, Rather, Mohd Ashraf, Khan, Azmat Ali, Alshehri, Jamilah M., Akash, Shopnil, Nepovimova, Eugenie, Kuca, Kamil, and Sharma, Rohit more...
- Published
- 2023
- Full Text
- View/download PDF
19. Regulating the disenfranchised: Reciprocity & resistance under the Mental Capacity Act
- Author
-
Fletcher, James Rupert
- Published
- 2023
- Full Text
- View/download PDF
20. The Alzheimers Disease Neuroimaging Initiative Neuropathology Core: An update.
- Author
-
Perrin, Richard, Franklin, Erin, Bernhardt, Haley, Burns, Aime, Schwetye, Katherine, Cairns, Nigel, Baxter, Michael, Weiner, Michael, and Morris, John
- Subjects
Alzheimer ,Alzheimers Disease Neuroimaging Initiative ,Lewy body ,TAR DNA binding protein 43 ,biomarker ,neuropathology ,Humans ,Alzheimer Disease ,Neuroimaging ,Aged ,Brain ,Female ,Biomarkers ,Male ,Aged ,80 and over ,Neuropathology ,Cohort Studies ,Sensitivity and Specificity - Abstract
INTRODUCTION: Biomarkers for Alzheimers disease neuropathologic change (ADNC) have been instrumental in developing effective disease-modifying therapeutics. However, to prevent/treat dementia effectively, we require biomarkers for non-AD neuropathologies; for this, neuropathologic examinations and annotated tissue samples are essential. METHODS: We conducted clinicopathologic correlation for the first 100 Alzheimers Disease Neuroimaging Initiative (ADNI) Neuropathology Core (NPC) cases. RESULTS: Clinical syndromes in this cohort showed 95% sensitivity and 79% specificity for predicting high/intermediate ADNC, a 21% false positive rate, and a ∼44% false negative rate. In addition, 60% with high/intermediate ADNC harbored additional potentially dementing co-pathologies. DISCUSSION: These results suggest that clinical presentation imperfectly predicts ADNC and that accurate prediction of high/intermediate ADNC does not exclude co-pathology that may modify presentation, biomarkers, and therapeutic responses. Therefore, new biomarkers are needed for non-AD neuropathologies. The ADNI NPC supports this mission with well-characterized tissue samples (available through ADNI and the National Institute on Aging) and gold-standard diagnostic information (soon to include digital histology). HIGHLIGHTS: The Alzheimers Disease Neuroimaging Initiative (ADNI) Neuropathology Core (NPC) brain donation cohort now exceeds 200 cases. ADNI NPC data in National Alzheimers Coordinating Center format are available through the Laboratory of Neuro Imaging. Digitized slide files from the ADNI NPC will be available in 2025. Requests for ADNI brain tissue samples can be submitted online for ADNI/National Institute on Aging evaluation. Clinical diagnoses of Alzheimers disease (AD)/AD and related dementias (ADRD) do not always predict post mortem neuropathology. Neuropathology is essential for the development of novel AD/ADRD biomarkers. more...
- Published
- 2024
21. Alzheimer's disease biomarkers and the tyranny of treatment
- Author
-
Karlawish, Jason and Grill, Joshua D
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Biomedical Imaging ,Dementia ,Acquired Cognitive Impairment ,Neurosciences ,Alzheimer's Disease ,Aging ,Neurodegenerative ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Brain Disorders ,4.2 Evaluation of markers and technologies ,2.1 Biological and endogenous factors ,Neurological ,Good Health and Well Being ,Alzheimer Disease ,Humans ,Biomarkers ,Positron-Emission Tomography ,Disease Management ,Prognosis ,Alzheimer ,Biomarker ,Clinical Sciences ,Public Health and Health Services ,Clinical sciences ,Epidemiology - Abstract
Advances in treatment are changing not only the therapeutic options for patients with Alzheimer's disease; they're also changing their diagnostic options. Technologies to detect amyloid such as PET imaging and blood or CSF testing now have a central role in Alzheimer's disease care. Notably, this role has been made possible by regulatory approval and coverage by payers of therapies. Access to treatments and the diagnostic tests needed to prescribe them is encourageing but it reveals a problem. These tests are tailored to the needs of the therapies, not to the needs of patients. Patients and families need to understand the causes of their impairments and their prognosis. This requires access to the best available diagnostic tests and this access should not depend on the availability of treatments. These tests should be used to their fullest capacity to inform patients of the causes of their cognitive impairments and their prognosis. Unfortunately, compared to diagnostic testing, treatment options are overvalued. We call this problem the tyranny of treatment. more...
- Published
- 2024
22. Investigating Acoustic and Psycholinguistic Predictors of Cognitive Impairment in Older Adults: Modeling Study.
- Author
-
Badal, Varsha, Reinen, Jenna, Twamley, Elizabeth, Lee, Ellen, Fellows, Robert, Bilal, Erhan, and Depp, Colin
- Subjects
AI ,Alzheimer ,CI ,MCI ,ML ,NLP ,acoustic ,algorithm ,algorithms ,artificial intelligence ,cognitive disability ,cognitive impairment ,cognitive limitation ,cognitive restriction ,dementia ,early detection ,early warning ,machine learning ,mild cognitive impairment ,natural language processing ,neurocognition ,neurocognitive disorder ,neurological decline ,practical model ,practical models ,predictive analytics ,predictive model ,predictive models ,predictive system ,psycholinguistic ,speech ,speech marker ,speech markers ,Humans ,Female ,Male ,Cognitive Dysfunction ,Aged ,80 and over ,Aged ,Psycholinguistics ,Neuropsychological Tests - Abstract
BACKGROUND: About one-third of older adults aged 65 years and older often have mild cognitive impairment or dementia. Acoustic and psycho-linguistic features derived from conversation may be of great diagnostic value because speech involves verbal memory and cognitive and neuromuscular processes. The relative decline in these processes, however, may not be linear and remains understudied. OBJECTIVE: This study aims to establish associations between cognitive abilities and various attributes of speech and natural language production. To date, the majority of research has been cross-sectional, relying mostly on data from structured interactions and restricted to textual versus acoustic analyses. METHODS: In a sample of 71 older (mean age 83.3, SD 7.0 years) community-dwelling adults who completed qualitative interviews and cognitive testing, we investigated the performance of both acoustic and psycholinguistic features associated with cognitive deficits contemporaneously and at a 1-2 years follow up (mean follow-up time 512.3, SD 84.5 days). RESULTS: Combined acoustic and psycholinguistic features achieved high performance (F1-scores 0.73-0.86) and sensitivity (up to 0.90) in estimating cognitive deficits across multiple domains. Performance remained high when acoustic and psycholinguistic features were used to predict follow-up cognitive performance. The psycholinguistic features that were most successful at classifying high cognitive impairment reflected vocabulary richness, the quantity of speech produced, and the fragmentation of speech, whereas the analogous top-ranked acoustic features reflected breathing and nonverbal vocalizations such as giggles or laughter. CONCLUSIONS: These results suggest that both acoustic and psycholinguistic features extracted from qualitative interviews may be reliable markers of cognitive deficits in late life. more...
- Published
- 2024
23. Toxoplasma gondii: A possible etiologic agent for Alzheimer's disease
- Author
-
Nayeri, Tooran, Sarvi, Shahabeddin, Sharif, Mehdi, and Daryani, Ahmad
- Published
- 2021
- Full Text
- View/download PDF
24. The Use of Natural Products for Preventing Cognitive Decline/Providing Neuroprotection
- Author
-
Tabatabaei-Malazy, Ozra, Azizi, Bayan, Abdollahi, Mohammad, Michel, Martin C., Editor-in-Chief, Barrett, James E., Editorial Board Member, Centurión, David, Editorial Board Member, Flockerzi, Veit, Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Meier, Kathryn Elaine, Editorial Board Member, Page, Clive P., Editorial Board Member, Seifert, Roland, Editorial Board Member, Wang, KeWei, Editorial Board Member, Wainwright, Cherry L., editor, and Schini-Kerth, Valerie B., editor more...
- Published
- 2025
- Full Text
- View/download PDF
25. PIPNet3D: Interpretable Detection of Alzheimer in MRI Scans
- Author
-
De Santi, Lisa Anita, Schlötterer, Jörg, Scheschenja, Michael, Wessendorf, Joel, Nauta, Meike, Positano, Vincenzo, Seifert, Christin, Goos, Gerhard, Series Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Celebi, M. Emre, editor, Reyes, Mauricio, editor, Chen, Zhen, editor, and Li, Xiaoxiao, editor more...
- Published
- 2025
- Full Text
- View/download PDF
26. ML Design in Handwriting Analysis for Classification of Alzheimer’s Disease
- Author
-
Caraveo, Fabián Cienfuegos, Álvarez Cruz, Karely A., Quintana, Marianna Pacheco, Romero Ramos, Elma N., Flores, Celia María Quiñonez, Figueroa, Carlos Eduardo Cañedo, Magjarević, Ratko, Series Editor, Ładyżyński, Piotr, Associate Editor, Ibrahim, Fatimah, Associate Editor, Lackovic, Igor, Associate Editor, Rock, Emilio Sacristan, Associate Editor, Flores Cuautle, José de Jesús Agustín, editor, Benítez-Mata, Balam, editor, Reyes-Lagos, José Javier, editor, Hernandez Acosta, Humiko Yahaira, editor, Ames Lastra, Gerardo, editor, Zuñiga-Aguilar, Esmeralda, editor, Del Hierro-Gutierrez, Edgar, editor, and Salido-Ruiz, Ricardo Antonio, editor more...
- Published
- 2025
- Full Text
- View/download PDF
27. DEMNET NeuroDeep: Alzheimer detection using electroencephalogram and deep learning.
- Author
-
Joshi, Vaishali M., Dandavate, Prajkta P., Rashmi, R., Shinde, Gitanjali R., Kulkarni, Deepthi D., and Mirajkar, Riddhi
- Subjects
ARTIFICIAL neural networks ,LONG short-term memory ,DEEP learning ,ALZHEIMER'S disease ,DIFFERENTIAL entropy - Abstract
Alzheimer's disease (AD) stands out as the most prevalent neurological brain disorder, and its diagnosis relies on various laboratory techniques. The electroencephalogram (EEG) emerges as a valuable tool for identifying AD, offering a quick, cost-effective, and readily accessible means of detecting early-stage dementia. Detecting AD in its early stages is crucial, as early intervention yields more successful outcomes and entails fewer risks than treating the disease at a later stage. The objective of this research is to create an advanced diagnosis system for AD using machine learning (ML) and EEG data. The proposed system utilizes a multilayer perceptron (MLP) and a deep neural network with bidirectional long short-term memory (BiLSTM) as the classifier. The feature extraction process involves incorporating Hjorth parameters, power spectral density (PSD), differential asymmetry (DASM), and differential entropy (DE). The BiLSTM classifier, particularly when combined with DE, exhibits outstanding performance with an accuracy of 97.27%. This amalgamation of DE and the deep neural network surpasses current state-of-the-art techniques, underscoring the substantial potential of this approach for precise and advanced diagnosis of AD. [ABSTRACT FROM AUTHOR] more...
- Published
- 2025
- Full Text
- View/download PDF
28. Convolutional Cross-Modal Autoencoder-Based Few-Shot Learning for Data Augmentation with Application to Alzheimer Dementia Diagnosis.
- Author
-
Bazine, Othmane, Rai, Omar, Aiadi, Oussama, Hedjam, Rachid, Khaldi, Belal, and Zhong, Guoqiang
- Abstract
This paper presents a novel deep few-shot learning method for magnetic resonance images-based Alzheimer’s dementia (AD) diagnosis. The proposed method consists of two main phases namely data augmentation and data classification. With regard to data augmentation and, to deal with data scarcity issues, we designed a convolutional cross-modal autoencoder (CCMAE) model for data generation. This model, which consists of two encoders and one decoder, receives two image modalities namely longitudinal and cross-section MRI, and generates a new cross-section image. We opt for a convolutional version of the autoencoder to capture the spatial information more effectively and reduce the number of trainable parameters. Moreover, to make the model able to perform deep analysis of input image, we establish a skip connection strategy between the first encoder and the decoder similar to the UNet mechanism. With regard to classification, we design a convolutional neural network-based model in which both textual and visual features are fused to strengthen the network performance and produce more reliable decisions. A comprehensive experiment on a publicly available dataset has been conducted to demonstrate the effectiveness of the proposed method compared to some related works. The code is publicly available at: . [ABSTRACT FROM AUTHOR] more...
- Published
- 2025
- Full Text
- View/download PDF
29. Exploration of alzheimer disease using design of experiments.
- Author
-
Gupta, Pranav, Pandey, Kavita, and Gupta, Sanskar
- Subjects
ALZHEIMER'S disease ,FACTOR analysis ,MINI-Mental State Examination ,EXPERIMENTAL design ,MEDICAL research ,FACTORIAL experiment designs - Abstract
This study examines the use of experimental designs, specifically full and fractional factorial designs, for predicting Alzheimer's disease with fewer variables. The full factorial design systematically investigates the effects of selected factors, providing a comprehensive analysis of their individual and interactive impacts on Alzheimer's prediction. On the other hand, the fractional factorial design simplifies the model by selecting key factors and removing non-significant ones. For Alzheimer's, among all the factors examined, the MMSE (Mini-mental state Examination) score emerged as the most significant, which was further cross-validated using Minitab Software Analysis. Importantly, the findings suggest that the fractional factorial design is a better alternative, particularly when time and cost constraints are present. The results highlight the effectiveness and efficiency of these experimental designs, demonstrating their potential for early detection, prevention, and treatment of Alzheimer's disease. By contributing to the expanding knowledge base on experimental designs in medical research, this study emphasizes their crucial role in understanding and combating complex diseases like Alzheimer's. [ABSTRACT FROM AUTHOR] more...
- Published
- 2025
- Full Text
- View/download PDF
30. Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer's disease: a case series.
- Author
-
Wagemann, Olivia, Brendel, Matthias, Franzmeier, Nicolai, Nübling, Georg, Gnörich, Johannes, Zaganjori, Mirlind, Prix, Catharina, Stockbauer, Anna, Wlasich, Elisabeth, Loosli, Sandra V., Sandkühler, Katja, Frontzkowski, Lukas, Höglinger, Günter, and Levin, Johannes more...
- Subjects
DISEASE risk factors ,POSITRON emission tomography ,PEOPLE with Down syndrome ,ALZHEIMER'S disease ,DOWN syndrome - Abstract
Purpose of the report: Adults with Down Syndrome (DS) have a substantially increased risk for Alzheimer's disease (AD) due to the triplicated amyloid-precursor-protein gene on chromosome 21, resulting in amyloid and tau accumulation. However, tau PET assessments are not sufficiently implemented in DS-AD research or clinical work-up, and second-generation tau tracers such as [
18 F]PI-2620 have not been thoroughly characterized in adults with DS. We aim at illustrating feasibility and potential diagnostic value of tau PET imaging with [18 F]PI-2620 for the diagnosis of DS-AD. Materials and methods: Five adults with DS (40% female, aged 43–62) and cognitive decline underwent clinical assessments, neuropsychological testing, lumbar puncture and multimodal neuroimaging. All underwent [18 F]PI-2620 tau PET. Visual read of tau PET scans was performed by three blinded raters, assessing increased tracer uptake in brain areas corresponding to the six Braak stage regions and basal ganglia. Results: Visual read of tau burden revealed three tau-positive individuals which corresponded to their clinical decline while two cognitively stable individuals were rated as negative. Rating showed high inter-rater reliability for all Braak stages. Conclusion: Tau PET imaging is a feasible and important biomarker assessment in the differential diagnosis of cognitive decline in adults with DS at risk of developing AD. [ABSTRACT FROM AUTHOR] more...- Published
- 2025
- Full Text
- View/download PDF
31. Carvacrol Essential Oil as a Neuroprotective Agent: A Review of the Study Designs and Recent Advances.
- Author
-
Tareen, Fahad Khan, Catenacci, Laura, Perteghella, Sara, Sorrenti, Milena, and Bonferoni, Maria Cristina
- Subjects
- *
ALZHEIMER'S disease , *BRAIN injuries , *ESSENTIAL oils , *PARKINSON'S disease , *CARVACROL , *CENTRAL nervous system , *MONOTERPENES - Abstract
Neurodegenerative diseases were mostly perceived as diseases of ageing populations, but now-a-days, these diseases pose a threat to populations of all age groups despite significant improvements in quality of life. Almost all essential oils (EOs) have been reported to have some neuroprotective abilities and have been used as supplements for good mental health over the centuries. This review highlights the therapeutic potential of one such monoterpene phenolic EO, carvacrol (CV), that has the potential to be used as a main therapeutic intervention for neurodegenerative disorders. Three libraries, Google Scholar, PubMed, and ScienceDirect, were explored for research studies related to the neuroprotective roles of CV. All the research articles from these libraries were sorted out, with the first article tracing back to 2009, and the latest article was published in 2024. The positive effects of CV in the treatment of Alzheimer's and Parkinson's Diseases, multiple sclerosis, ischemia, and behavioural disorders have been supported with evidence. This review not only focused on study designs and the pharmacological pathways taken by CV for neuroprotection but also focused on demographics, illustrating the trend of CV research studies in certain countries and the preferences for the use of in vitro or in vivo models in studies. Our review provides useful evidence about the neuroprotective potential of CV; however, a lack of studies was observed regarding CV encapsulation in proper dosage forms, in particular nanoparticles, which could be further explored for CV delivery to the central nervous system. [ABSTRACT FROM AUTHOR] more...
- Published
- 2025
- Full Text
- View/download PDF
32. Evaluation of serum NFL, T-tau, p-tau181, p-tau217, Aβ40 and Aβ42 for the diagnosis of neurodegenerative diseases.
- Author
-
Kahouadji, Samy, Pereira, Bruno, Sapin, Vincent, Valentin, Audrey, Bonnet, Agathe, Dionet, Elsa, Durif, Julie, Lahaye, Clément, Boisgard, Stéphane, Moisset, Xavier, and Bouvier, Damien
- Subjects
- *
ALZHEIMER'S disease , *PARKINSONIAN disorders , *TAU proteins , *NEURODEGENERATION , *RECEIVER operating characteristic curves - Abstract
To assess the variations and diagnostic performance of serum biomarkers of neurodegenerative diseases. In this monocentric prospective study, neurofilament light (NFL), T-tau, p-tau181, p-tau217, Aβ40, and Aβ42 were measured in serum collected from orthopedic patients (control group, n=114) and patients in the neurology department (n=69) previously diagnosed with Alzheimer's disease (AD, n=52), parkinsonian syndromes (n=10), and other etiologies of neurodegeneration (non-AD, n=7). In the control group, serum NFL, T-tau, p-tau181, p-tau217, and Aβ40 significantly increased with age, independently of sex. NFL (p=0.0078), p-tau217 (p<0.001) were significantly increased with neurodegeneration when compared to controls, with only p-tau217 significant in the multivariate analysis (p<0.001). Multivariate regression analysis accounting for age highlighted a significant increase of p-tau217 (p<0.001) in the AD subgroup. NFL was significantly increased in the non-AD patients (p<0.001), and in the parkinsonian syndromes subgroup (p=0.016) when compared to negative controls. Serum p-tau181 and p-tau217 were significantly correlated with CSF p-tau181 (Spearman's coefficients of 0.43 and 0.48 respectively, n=40). Areas under the ROC curves for the identification of patients with neurodegenerative diseases were 0.62 (0.54–0.70) for NFL, 0.62 (0.54–0.71) for T-tau, 0.83 (0.76–0.89) for p-tau217, and 0.66 (0.58–0.74) for Aβ40. Serum biomarkers can help identify patients with neurodegenerative disease and may be a valuable tool for care and orientation. Phosphorylated tau p-tau217 is a promising blood biomarker for AD and NFL for other etiologies. [ABSTRACT FROM AUTHOR] more...
- Published
- 2025
- Full Text
- View/download PDF
33. Exploring SERPINA3 as a neuroinflammatory modulator in Alzheimer’s disease with sex and regional brain variations.
- Author
-
Sanfilippo, Cristina, Castrogiovanni, Paola, Imbesi, Rosa, Vecchio, Michele, Sortino, Martina, Musumeci, Giuseppe, Vinciguerra, Manlio, and Di Rosa, Michelino
- Abstract
SERPINA3, a serine protease inhibitor, is strongly associated with neuroinflammation, a typical condition of AD. Its expression is linked to microglial and astrocytic markers, suggesting it plays a significant role in modulating neuroinflammatory responses. In this study, we examined the SERPINA3 expression levels, along with CHI3L1, in various brain regions of AD patients and non-demented healthy controls (NDHC). Nineteen microarray datasets were analyzed, with brain samples stratified by sex and age from areas including the prefrontal cortex, occipital lobe, and cerebellum. Results showed that SERPINA3 was significantly highly expressed in AD patients compared to NDHCs only in males. Sex-specific differences were observed only in NDHCs, where females had higher SERPINA3 levels than males. ROC analysis suggested that SERPINA3 could be a strong marker for distinguishing AD in males but not females. In NDHCs, SERPINA3 expression correlated more strongly with age than in AD patients. In brain regions, SERPINA3 expression in NDHC females was higher across multiple areas, while in AD patients, this difference was limited to the prefrontal cortex. The most significant differences between NDHC and AD patients were found in the occipital and prefrontal regions. Furthermore, we identified a potential nuclear localization for SERPINA3, supported by immunohistochemistry analysis from The Human Protein Atlas. Correlation with neuropathological traits, including Clinical Dementia Rating (CDR) and Braak Neurofibrillary Tangle Score, showed positive significant associations between SERPINA3 and CDR in AD patients. Performing a docking analysis, we revealed an interaction region between SERPINA3 and CHI3L1 proteins, suggesting a potential role in AD. Tissue transcriptomic deconvolution analysis indicated a significant overlap between SERPINA3 expression and microglial/astrocytic signatures, suggesting that SERPINA3 plays a key role in modulating neuroinflammation in AD. SERPINA3 was significantly overexpressed in male AD patients compared to NDHCs, while no such difference was observed in females. In NDHCs, sex-specific differences were evident, with females showing higher SERPINA3 levels than males. Regionally, NDHC females exhibited higher SERPINA3 expression across multiple brain areas, whereas in AD patients, this elevation was restricted to the prefrontal cortex. SERPINA3 expression in NDHCs was also found to correlate with astrocyte and microglia profiles. Structural analysis suggested a potential nuclear localization for SERPINA3, while docking analysis identified key interaction regions between SERPINA3 and CHI3L1 proteins, hinting at a functional relationship in AD. Furthermore, TTDA revealed a strong overlap between SERPINA3 expression and microglial/astrocytic genes signatures, underscoring its pivotal role in modulating neuroinflammation in AD. [ABSTRACT FROM AUTHOR] more...
- Published
- 2025
- Full Text
- View/download PDF
34. Mitochondrial bioenergetics stimulates autophagy for pathological MAPT/Tau clearance in tauopathy neurons.
- Author
-
Jia, Nuo, Ganesan, Dhasarathan, Guan, Hongyuan, Jeong, Yu Young, Han, Sinsuk, Rajapaksha, Gavesh, Nissenbaum, Marialaina, Kusnecov, Alexander W., and Cai, Qian
- Subjects
FLUORESCENCE resonance energy transfer ,CYTOCHROME oxidase ,DORSAL root ganglia ,TAU proteins ,TAUOPATHIES - Abstract
Hyperphosphorylation and aggregation of MAPT (microtubule-associated protein tau) is a pathogenic hallmark of tauopathies and a defining feature of Alzheimer disease (AD). Pathological MAPT/tau is targeted by macroautophagy/autophagy for clearance after being sequestered within autophagosomes, but autophagy dysfunction is indicated in tauopathy. While mitochondrial bioenergetic deficits have been shown to precede MAPT/tau pathology in tauopathy brains, it is unclear whether energy metabolism deficiency is involved in the pathogenesis of autophagy defects. Here, we reveal that stimulation of anaplerotic metabolism restores defective oxidative phosphorylation (OXPHOS) in tauopathy neurons which, strikingly, leads to pronounced MAPT/tau clearance by boosting autophagy functionality through enhancements of mitochondrial biosynthesis and supply of phosphatidylethanolamine for autophagosome biogenesis. Furthermore, early anaplerotic stimulation of OXPHOS elevates autophagy activity and attenuates MAPT/tau pathology, thereby counteracting memory impairment in tauopathy mice. Taken together, our study sheds light on a pivotal role of mitochondrial bioenergetic deficiency in tauopathy-related autophagy defects and suggests a new therapeutic strategy to prevent the buildup of pathological MAPT/tau in AD and other tauopathy diseases. Abbreviation: AA: antimycin A; AD, Alzheimer disease; ATP, adenosine triphosphate; AV, autophagosome/autophagic vacuole; AZ, active zone; Baf-A1: bafilomycin A
1 ; CHX, cycloheximide; COX, cytochrome c oxidase; DIV, days in vitro; DRG, dorsal root ganglion; ETN, ethanolamine; FRET, Förster/fluorescence resonance energy transfer; FTD, frontotemporal dementia; Gln, glutamine; HA: hydroxylamine; HsMAPT/Tau, human MAPT; IMM, inner mitochondrial membrane; LAMP1, lysosomal-associated membrane protein 1; LIs, lysosomal inhibitors; MDAV, mitochondria-derived autophagic vacuole; MmMAPT/Tau, murine MAPT; NFT, neurofibrillary tangle; OCR, oxygen consumption rate; Omy: oligomycin; OXPHOS, oxidative phosphorylation; PPARGC1A/PGC-1alpha: peroxisome proliferative activated receptor, gamma, coactivator 1 alpha; PE, phosphatidylethanolamine; phospho-MAPT/tau, hyperphosphorylated MAPT; PS, phosphatidylserine; PISD, phosphatidylserine decarboxylase;SQSTM1/p62, sequestosome 1; STX1, syntaxin 1; SYP, synaptophysin; Tg, transgenic; TCA, tricarboxylic acid; TEM, transmission electron microscopy. [ABSTRACT FROM AUTHOR] more...- Published
- 2025
- Full Text
- View/download PDF
35. Memantine/Rosuvastatin Therapy Abrogates Cognitive and Hippocampal Injury in an Experimental Model of Alzheimer's Disease in Rats: Role of TGF-β1/Smad Signaling Pathway and Amyloid-β Clearance.
- Author
-
Zidan, Esraa F., El-Mezayen, Nesrine S., Elrewini, Safaa H., Afify, Elham A., and Ali, Mennatallah A.
- Abstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder of complex pathogenesis and multiple interacting signaling pathways where amyloidal-β protein (Aβ) clearance plays a crucial role in cognitive decline. Herein, the current study investigated the possible modulatory effects of memantine/ rosuvastatin therapy on TGF-β1/p-Smad/p21 signaling pathway and their correlation to the blood brain barrier transporters involved in Aβ-clearance and microRNAs as a novel molecular mechanism in AD treatment. AD was induced by a single intracerebroventricular streptozotocin injection (ICV-STZ, 3 mg/kg) in rats and drug therapy was continued for 28 days after AD induction. Efficacy was monitored by applying a battery of behavioral assessments, as well as biochemical, histopathological, molecular and gene expression techniques. The upregulated TGF-β1-signaling in the untreated rats was found to be highly correlated to transporters and microRNAs governing Aβ-efflux; ABCA1/miRNA-26 and LRP1/miRNA-205 expressions, rather than RAGE/miRNA-185 controlling Aβ-influx; an effect that was opposed by the tested drugs and was found to be correlated with the abolished TGF-β1-signaling as well. Combined memantine/rosuvastatin therapy ameliorated the STZ evoked decreases in escape latency and number of crossovers in the Morris water maze test, % spontaneous alternation in the Y-maze test, and discrimination and recognition indices in the object recognition test. The evoked behavioral responses were directly related to the β-amyloid accumulation and the alteration in its clearance. Additionally, drug treatment increased brain glutathione and decreased malondialdehyde levels. These findings were histopathologically confirmed by a marked reduction of gliosis and restoration of neuronal integrity in the CA1 region of the hippocampus of the AD rats. These findings implicated that the memantine/rosuvastatin combination could offer a new therapeutic potential for AD management by abrogating the TGF-β1/p-Smad2/p21 pathway and regulating Aβ-clearance. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
36. Phytochemical constituents analysis in laminaria digitata for Alzheimer's disease: molecular docking and in-silico toxicity approach.
- Author
-
Adella Putri, Angelina Deva, Sembiring, Mikael Ham, and Tuba, Syahrul
- Subjects
- *
ARYL hydrocarbon receptors , *ALZHEIMER'S disease , *ALGINIC acid , *POISONS , *AMINO acid residues , *LAMINARIA , *ACETYLCHOLINESTERASE - Abstract
Alzheimer's disease (AD) is a common brain disease associated with cognitive impairment and dementia. donepezil, an acetylcholinesterase (AChE) inhibitor drug as a commercial AD drug represents a non-cost-effective treatment with the toxic effects reported. As the prevalence of AD increases, the development of effective therapeutic treatments is urgently required. Laminaria digitata is a brown seaweed claimed to be able to prevent and treat neurodegenerative diseases. Therefore, this study measured and compared the binding affinity and toxicity of seven common phytoconstituents in Laminaria digitata against acetylcholinesterase (AChE) with those of donepezil using a molecular docking approach. The binding free energy values of donepezil, dieckol, eckol, fucodiphlorethol G, 7-Phloroecol, laminaran, alginic acid, and fucoidan with acetylcholinesterase (AChE) were −12.3, −13.5, −10.5, −8,7, −9.7, −8.0, −10.3, and −7.4 kcal/mol. All ligands constantly interacted with the AChE amino acid residues, namely Tyr124. Dieckol, with the strongest and most stable interaction, is classified as class IV toxicity, with an LD50 value of 866 mg/kg. It has aryl hydrocarbon receptor (AhR) and mitochondrial membrane potential (MMP) toxicity at certain doses. Theoretically, based on Lipinski's rule, dieckol is likely to have poor absorption and permeation properties; therefore, several considerations during the drug discovery process are needed. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
37. Identifying Hub Genes and miRNAs Associated with Alzheimer's Disease: A Bioinformatics Pathway to Novel Therapeutic Strategies.
- Author
-
Gascón, Elisa, Calvo, Ana Cristina, Molina, Nora, Zaragoza, Pilar, and Osta, Rosario
- Subjects
- *
AMYLOID beta-protein , *ALZHEIMER'S disease , *GENE regulatory networks , *OLDER people , *SENSORY perception - Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that mainly affects the elderly population. It is characterized by cognitive impairment and dementia due to abnormal levels of amyloid beta peptide (Aβ) and axonal Tau protein in the brain. However, the complex underlying mechanisms affecting this disease are not yet known, and there is a lack of standardized biomarkers and therapeutic targets. Therefore, in this study, by means of bioinformatics analysis, AD-affected brain tissue was analyzed using the GSE138260 dataset, identifying 612 differentially expressed genes (DEGs). Functional analysis revealed 388 upregulated DEGs associated with sensory perception and 224 downregulated DEGs linked to the regulation and modulation of synaptic processes. Protein–protein interaction network analysis identified 20 hub genes. Furthermore, miRNA target gene networks revealed 1767 miRNAs linked to hub genes, among which hsa-mir-106a-5p, hsa-mir-17-5p, hsa-mir-26a-5p, hsa-mir-27a-3p and hsa-mir-34a-5p were the most relevant. This study presents novel biomarkers and therapeutic targets for AD by analyzing the information obtained with a comprehensive literature review, providing new potential targets to study their role in AD. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
38. Neuroprotective efficiency of celecoxib vesicular bilosomes for the management of lipopolysaccharide-induced Alzheimer in mice employing 23 full factorial design.
- Author
-
Darwish, Asmaa Badawy, Salama, Abeer, and Younis, Mostafa Mohammed
- Subjects
- *
ALZHEIMER'S disease , *BILE salts , *ZETA potential , *TRANSMISSION electron microscopy , *TOLL-like receptors - Abstract
The aim of this study was to develop and evaluate bilosomes loaded with Celecoxib (CXB) for the efficient treatment of Alzheimer. The thin-film hydration approach was utilized in the formulation of CXB bilosomes (CXB-BLs). The study used a 23-factorial design to investigate the impact of several formulation variables. Three separate parameters were investigated: bile salt type (X1), medication amount (X2), and lipid–bile salt ratio (X3). The dependent responses included entrapment efficiency (Y1: EE %), particle size (Y2: PS), and zeta potential (Y3: ZP). The formulation factors were statistically optimized using the Design-Expert® program. The vesicles demonstrated remarkable CXB encapsulation efficiency, ranging from 94.16 ± 1.91 to 98.38 ± 0.85%. The vesicle sizes ranged from 241.8 ± 6.74 to 352 ± 2.34 nm. The produced formulations have high negative zeta potential values, indicating strong stability. Transmission electron microscopy (TEM) revealed that the optimized vesicles had a spherical form. CXB release from BLs was biphasic, with the release pattern following Higuchi's model. In vivo studies confirmed the efficiency of CXB-BLs in management of lipopolysaccharide-induced Alzheimer as CXB-BLs ameliorated cognitive dysfunction, decreased acetylcholinesterase (AChE), and inhibited neuro-inflammation and neuro-degeneration through reducing Toll-like receptor (TLR4), and Interleukin-1β (IL-1β) levels. The findings suggested that the created CXB-BLs could be a potential drug delivery strategy for Alzheimer's treatment. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
39. Assessment of primary health-care providers' knowledge of Alzheimer's disease in Turkey.
- Author
-
Ayhan, Yunus Emre, Özmen, Muhammet, Ozturk, Nur, and Aksoy, Nilay
- Abstract
Purpose: Alzheimer's disease (AD) is the primary cause of dementia in elderly people and needs extensive professional care. The aim of our study was to assess the level of knowledge among primary health-care providers, primarily Family Physicians (FPs) and community pharmacists (CPs), about AD and its treatment. Design/methodology/approach: A cross-sectional study using Google Forms sent by email or message to FPs and CPs in Istanbul in June–July 2023. Turkish modified the Alzheimer's Disease Knowledge Scale (ADKS) and Alzheimer's Medicines Knowledge Level Questionnaire (AMKLQ) were used in this study. Findings: A total of 63 FPs with a mean age of 35.3 ± 7.8 and 138 CPs with a mean age of 38.6 ± 12.6 enrolled in the study. There was no statistically significant difference between FPs and CPs in terms of total ADKS score (19.82 ± 2.30 vs 19.23 ± 3.08, p = 0.136), but there was a significant difference in terms of total AMKLQ score (4.31 ± 1.40 vs 3.81 ± 1.49, p = 0.020). Health-care providers with Alzheimer's training had a higher total AMKLQ score (OR =1.08 CI 95% [1.03–1.14], p = 0.012). Originality/value: FPs' knowledge of AD is on par with that of CPs. Nevertheless, it has been observed that FPs have more proficiency in delivering accurate responses to the AMKLQ and ADKS inquiries, which encompass crucial details regarding the treatment of AD. The sole determinant of the highest mean AMKLQ score was found to be professional education. Collectively, these arguments emphasize the need for primary health-care practitioners to obtain comprehensive and ongoing education regarding AD and its treatment. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
40. Unveiling the Role of MicroRNA-132 on Alzheimer's Disease Brain Cells.
- Author
-
Kim, Hannah and Youngwook David Kim
- Subjects
MICRORNA ,ALZHEIMER'S disease ,MEDICAL personnel ,MEDICAL care ,THERAPEUTICS ,HEALTH outcome assessment - Abstract
Alzheimer's Disease (AD) is a neurological disease that degenerates memories and cognitive abilities. A key factor of the disease that is still being studied is microRNA (miRNA), a non-coding strand of RNA that regulates gene expression. Particularly, miRNA-132 is known to play a significant role in AD. Past research has shown that miRNA-132 functions as a negative regulator and slows down the progression of the disease in the later stages. Through this study, four genes were identified to be associated with the regulating G1/S transition: RB1, EP300, PTEN, and CDKN1A. These four genes were known to inhibit the G1/S transition. However, the result was contrary to our expectations because if the microRNA-132 activates G1/S transition in neurons by silencing these four genes, the neurofibrillary tangles and amyloid plaques may be formed, inducing apoptosis in neurons. We transfected miRNA-132 on A172 (human brain cell) to confirm this result. The miRNA-132 transfection cells showed decreased cell proliferation and increased cell death. This result indicates that microRNA-132 may advance the progression of AD in the early stages. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
41. Support vector machine method for classifying severity of Alzheimer's based on hippocampus object using magnetic resonance imaging modalities.
- Author
-
Supriyanti, Retno, Riyanto, Arif Pujo, Ramadhani, Yogi, Aliim, Muhammad Syaiful, Akbar, Muhammad Irham, Widodo, Haris Budi, and Alqaaf, Muhammad
- Subjects
ALZHEIMER'S disease ,MAGNETIC resonance imaging ,BRAIN degeneration ,SUPPORT vector machines ,COMPUTED tomography - Abstract
Alzheimer's disease is a degenerative brain condition that causes progressive decline in several aspects. Starting from memory, cognitive or thinking abilities, speaking abilities, and behavior. Currently, Alzheimer's diagnosis uses some methods, such as blood tests, scanning with computerized tomography scan (CT scan), or magnetic resonance imaging (MRI). As a reference for determining the level of severity, doctors usually use clinical dementia rating (CDR). CDR is a numerical scale used to measure the severity of dementia symptoms. The doctor will manually compare the patient's condition with those stated on the CDR. This condition will take quite a long time, and sometimes human error will occur. As technology and science develop, doctors can assist in manually detecting Alzheimer's using classification algorithms. Many methods can be used to classify, including the CDR support vector machine (SVM) method. Unfortunately, this method is usually only used to classify two classes. This technology allows the classification process to be carried out automatically and quickly. On the other hand, when using CDR to classify Alzheimer's severity, there are several scales, not just two classes. So, in this research, we modified the use of SVM to classify three levels of severity, namely scale 0 for normal, scale 1 for mild conditions, and scale 2 for moderate conditions. The experiments we carried out provided an accuracy of 90.9%. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
42. Risk of cognitive decline among patients with dengue virus infection: a systematic review.
- Author
-
Thangavelu, Lakshmi, Abdelwahab, Siddig Ibrahim, Farasani, Abdullah, Ballal, Suhas, Bansal, Pooja, Nathiya, Deepak, Kaur, Kiranjeet, Kumar, M Ravi, Sinha, Aashna, Alrasheed, Hayam A, Al-Subaie, Maha F, Kaabi, Nawal A Al, bshabshe, Ali Al, Fares, Mona A Al, Albayat, Hawra, Rabaan, Ali A, Pant, Kumud, Zahiruddin, Quazi Syed, Rao, Arathi P, and Khatib, Mahalaqua Nazli more...
- Subjects
DENGUE viruses ,VIRUS diseases ,COGNITION disorders ,VASCULAR dementia ,ALZHEIMER'S disease ,DENGUE - Abstract
Dengue fever, caused by the dengue virus and transmitted through Aedes mosquitoes, is a growing public health concern, particularly in tropical and subtropical regions. Traditionally associated with febrile and hemorrhagic symptoms, recent research suggests a potential link between dengue and cognitive impairments. This systematic review assessed existing research to understand the association between dengue virus infection and cognitive impairments, including dementia, Alzheimer disease, memory loss, and confusion. This systematic review followed preferred reporting items for systematic reviews and meta-analyses guidelines. A comprehensive literature search was conducted in PubMed, EMBASE, and Web of Science up to January 18, 2024. Studies examining the prevalence and association of cognitive impairments in dengue patients were included. Data extraction and quality assessment were performed using Nested Knowledge software and the Newcastle-Ottawa Scale. Of the 1129 articles identified, 5 were included in the review, covering a total of 200 873 participants from Taiwan, Brazil, and France. Evidence from population-based cohort studies indicated short-term cognitive impairments, including confusion and memory loss, in some dengue patients. Additionally, long-term risks of dementia, including Alzheimer disease and vascular dementia, were observed, particularly among older adults. Although the findings suggest there might be an association between dengue infection and cognitive decline, the mechanisms underlying this link remain unclear. This systematic review suggests that dengue virus infection may affect cognitive function in both acute and long-term contexts. However, the current evidence is not strong enough to establish a conclusive link. Further research with larger sample sizes and longitudinal studies is essential to confirm the impact of dengue virus on cognitive health. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
43. Expérience d'une unité pilote spécialisée en soins médicaux et de réadaptation dédiée aux patients souffrant d'une maladie neuro-évolutive au décours d'une décompensation somatique aiguë.
- Author
-
Thiriat, Franck and Bertin-Ciftci, Josephine
- Subjects
PATIENT autonomy ,NEUROBEHAVIORAL disorders ,NEURODEGENERATION ,MEDICAL care ,MEDICAL rehabilitation - Abstract
Copyright of Gériatrie et Psychologie Neuropsychiatrie du Vieillissement is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) more...
- Published
- 2024
- Full Text
- View/download PDF
44. A experiência pública do Alzheimer no YouTube: competências midiáticas como motores de aprendizagens sociais no canal O Bom do Alzheimer
- Author
-
Adriana Helena de Almeida Freitas and Rennan Lanna Martins Mafra
- Subjects
alzheimer ,midiatização ,experiência pública ,competências midiáticas ,aprendizagem ,Communication. Mass media ,P87-96 - Abstract
Este artigo investiga de que maneira a experiência midiatizada no canal Francisquinha Alves - O Bom do Alzheimer do YouTube contribui para o desenvolvimento de aprendizagens sociais, a partir da mobilização de competências midiáticas. Com base no paradigma indiciário de Braga, tomado como abordagem metodológica, a análise organiza essa experiência em quatro fases, que refletem habilidades associadas às competências midiáticas ao longo do tempo. Foram examinados 1.291 vídeos publicados entre 30 de julho de 2016 e 31 de julho de 2021. A partir das noções de midiatização em Braga e das dimensões da competência midiática de Ferrés e Piscitelli, identifica-se que a youtuber Cláudia não apenas desenvolve habilidades ao cuidar de sua mãe durante esse período, mas também aprimora sua capacidade de compartilhar esses aprendizados nas plataformas digitais. Paralelamente, a midiatização de sua trajetória promove o desenvolvimento de aprendizagens entre os públicos do canal. more...
- Published
- 2025
- Full Text
- View/download PDF
45. Neuropathology-based approach reveals novel Alzheimer's Disease genes and highlights female-specific pathways and causal links to disrupted lipid metabolism: insights into a vicious cycle
- Author
-
Yin Jin, Apostolia Topaloudi, Sudhanshu Shekhar, Guangxin Chen, Alicia Nicole Scott, Bryce David Colon, Petros Drineas, Chris Rochet, and Peristera Paschou
- Subjects
Alzheimer ,s disease ,Neuropathology ,Genomewide association study ,Sex-specific analysis ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Dementia refers to an umbrella phenotype of many different underlying pathologies with Alzheimer’s disease (AD) being the most common type. Neuropathological examination remains the gold standard for accurate AD diagnosis, however, most that we know about AD genetics is based on Genome-Wide Association Studies (GWAS) of clinically defined AD. Such studies have identified multiple AD susceptibility variants with a significant portion of the heritability unexplained and highlighting the phenotypic and genetic heterogeneity of the clinically defined entity. Furthermore, despite women’s increased susceptibility to dementia, there is a lack of sex-specific genetic studies and understanding of sex-specific background for the disorder. Here, we aim to tackle the heterogeneity of AD by specifically concentrating on neuropathological features and pursuing sex-specific analysis. We bring together 14 different genomic and neuropathology datasets (6960 individuals) and we integrate our GWAS findings with transcriptomic and phenotypic data aiming to also identify biomarkers for AD progression. We uncover novel genetic associations to AD neuropathology, including BIN1 and OPCML. Our sex-specific analysis points to a role for BIN1 specifically in women as well as novel AD loci including QRFPR and SGCZ. Post-GWAS analyses illuminate the functional and biological mechanisms underlying AD and reveal sex-specific differences. Finally, through PheWAS and Mendelian Randomization analysis, we identify causal links with AD neuropathology pointing to disrupted lipid metabolism, as well as impaired peripheral immune response and liver dysfunction as part of a vicious cycle that fuels neurodegeneration. more...
- Published
- 2025
- Full Text
- View/download PDF
46. Review of Postgraduate Dissertations on Alzheimer's Patients in Nursing Care
- Author
-
Fadime Toru
- Subjects
alzheimer ,nurse ,caregivers ,postgraduate theses ,Nursing ,RT1-120 - Abstract
Increasingly, health problems have started to occur in the increasing elderly population. The physical and psychological problems that occur with aging have brought the search for new care and treatment methods to the agenda, and with the increase in life expectancy, there has been an increase in the diseases that may occur in individuals. When the nursing literature was examined, it was determined that both physical and psychological problems were seen in patients diagnosed with Alzheimer's disease, and all these problems significantly affected the lives of patients and caregivers, and it was determined that the studies conducted were mostly at the international level. Although it is known that there are approximately 600 thousand Alzheimer's patients in our country and that there are many patients who have not yet been diagnosed, the number of studies used in the field of nursing other than postgraduate theses is very few. Therefore, the aim of this systematic review is to examine the studies conducted with Alzheimer's patients in postgraduate theses in the field of nursing in Turkey and to reveal the results. In the study, the type, year of publication, aim, sample, number, publication status, method and results of postgraduate theses in the field of nursing related to Alzheimer's patients were examined. The study was conducted between 15.07.2023-08.06.2024 by using the key words ‘Alzheimer, Alzheimer and caregivers, nursing’ from the YÖK National Thesis Centre database. The ‘thesis evaluation form’ prepared by the researchers was used for data collection. Descriptive statistics were used to evaluate the data. As a result of the search, 21 theses were found, 16 of which are master's theses and 5 are doctoral theses. Of the theses, 14% were conducted in 2017, 38.1% were conducted in the Department of Nursing, and 61.9% were descriptive. In the theses, 52.3% of the sample consisted of individuals caring for Alzheimer's patients. 52.4% of the theses were translated into publications. When the subject distribution of the theses was analyzed, 42.8% were found to be related to the difficulties experienced by the caregivers (care burden). In the study, 76.2% of the theses were made as master's theses. It was seen that 61.9% of the theses were of descriptive type and 52.4% of them were not published as articles. It is recommended to increase the number of studies with patients diagnosed with Alzheimer's disease and caregivers, to conduct randomized controlled studies, to improve the quality of postgraduate education, and to increase the number of doctoral thesis studies, which are currently limited in number. more...
- Published
- 2024
- Full Text
- View/download PDF
47. Multicomponent reactions driving the discovery and optimization of agents targeting central nervous system pathologies
- Author
-
Lucía Campos-Prieto, Aitor García-Rey, Eddy Sotelo, and Ana Mallo-Abreu
- Subjects
alzheimer ,depression ,epilepsy ,multicomponent reactions ,parkinson ,schizophrenia ,Science ,Organic chemistry ,QD241-441 - Abstract
The ongoing quest to discover effective treatments for diseases remains a significant challenge for the scientific community. Multicomponent reactions (MCRs) have emerged as powerful tools in accelerating drug discovery, enabling the rapid generation of chemical libraries with high diversity in a time-efficient and environmentally sustainable manner. In this review, we focus on central nervous system (CNS) disorders, particularly Alzheimer's disease, Parkinson's disease, schizophrenia, depression, and epilepsy, where MCRs have contributed to the development of promising ligands in recent years. Rather than providing an exhaustive overview, this review aims to highlight key studies that address major CNS pathologies, relevant drug targets, and various MCR approaches. We have carefully selected representative articles and apologize to the authors whose important contributions may not be included. By concentrating on these pivotal studies, we strive to offer a clear and concise perspective on current research trends and breakthroughs in this field. more...
- Published
- 2024
- Full Text
- View/download PDF
48. Doença De Alzheimer: Um Perfil Diagnóstico Dentro Da Estratégia De Saúde Da Família
- Author
-
Ronaldo Pontes Barreira Filho, Luís de França Camboim Neto, and Carla Soraya Costa Maia
- Subjects
doença ,alzheimer ,idoso ,estratégia de saúde da família ,Nursing ,RT1-120 ,Geriatrics ,RC952-954.6 ,Public aspects of medicine ,RA1-1270 - Abstract
Objetivo: O presente estudo teve como objetivo avaliar a condição de uma população de idosos inseridos na estratégia da Saúde da Família, no aspecto de incidência da doença. Métodos: Foram avaliados 118 idosos, divididos em grupos de 60-70, 71-80 e acima de 80 anos de idade, no período de abril a maio de 2008. A pesquisa foi realizada por meio de avaliação do quadro clínico, seguida por exame físico básico, exames complementares disponíveis pelo SUS e aplicação de questionários, pelos quais foram levantadas informações sobre estado mental, cognitivo, de orientação temporal e espacial de cada paciente. Foram avaliadas a memória imediata, a memória de evocação, a capacidade de raciocínio, o julgamento, a atenção a cálculos e linguagem, a alteração do humor e do comportamento. Resultados: No grupo estudado observou-se que, entre os idosos na faixa etária de 60-70 anos, 7,7% apresentaram diagnóstico provável de doença de Alzheimer, e 30,7%, diagnóstico possível; entre os idosos na faixa de 71-80 anos, 23% apresentaram diagnóstico provável, e 23%, diagnóstico possível. Entre o grupo de idosos acima de 80 anos, 36,3% apresentaram diagnóstico provável para doença de Alzheimer, e 27,4%, diagnóstico possível. Conclusão: O aumento do número de casos dessa doença ocorre com o aumento da idade, e o número de casos de pacientes não portadores da doença de Alzheimer ocorreu em ordem decrescente com a idade. more...
- Published
- 2024
49. Synthesis and anti-Alzheimer activity of new N-(5, 6-dimethyl-1H-benzo[d] imidazol-2-yl)-1-phenylmethanimine derivatives
- Author
-
Hiba Ali Hasan, Basma M. Abd Razik, and Mohammed Oday Ezzat
- Subjects
acetylcholinesterase ,alzheimer ,butyrylcholinesterase ,benzimidazole ,molecular docking ,Therapeutics. Pharmacology ,RM1-950 ,Pharmacy and materia medica ,RS1-441 - Abstract
The cholinesterase group, including acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), is responsible for inhibiting the actions of choline esters. Benzimidazole derivatives, renowned for their aromatic organic heterocyclic structure, exhibit diverse biological activities, including enzyme inhibitory effects. Imine compounds, easily synthesized, demonstrate notable biological efficacy against various pathogens and enzymes. Synthesize, purify, and characterize novel benzimidazole scaffolds, and evaluate their anti-Alzheimer’s activity by measuring AChE and BChE activities. A new series of benzimidazole phenylmethanimine derivatives (3a–3d) was synthesized through refluxing amine with various benzaldehydes. Products underwent purification by solvent washing and characterization using spectroscopic methods. In vitro anti-Alzheimer’s activity was assessed by measuring inhibitory activity (half-maximal inhibitory concentration [IC50]) against cholinesterase enzymes. the newly synthesized Schiff bases, purified solely by solvent washing, yielded high percentages (81%–91%). These derivatives showed significant inhibitory activity, with low IC50 values observed for compounds 3a and 3d against both enzymes. Molecular docking studies estimated binding energies and identified interacting amino acids in active pockets. Four new derivatives were synthesized with high yields using the classical reflux method. Purification involved solvent washing only, followed by direct spectroscopic analysis. In vitro inhibitory activities against AChE and BChE enzymes were observed, with compounds 3a and 3d showing promising results. Docking studies revealed higher inhibitory activity and lower IC50 values for two derivatives, indicating their potential as potent inhibitors. more...
- Published
- 2024
- Full Text
- View/download PDF
50. Air pollution: a latent key driving force of dementia
- Author
-
Mahdiyeh Mohammadzadeh, Amir Hossein Khoshakhlagh, and Jordan Grafman
- Subjects
Vascular dementia ,Non-Alzheimer dementia ,Air pollution ,Dementia ,Elderly ,Alzheimer ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Many researchers have studied the role of air pollutants on cognitive function, changes in brain structure, and occurrence of dementia. Due to the wide range of studies and often contradictory results, the present systematic review was conducted to try and clarify the relationship between air pollutants and dementia. To identify studies for this review, a systematic search was conducted in Scopus, PubMed, and Web of Science databases (without historical restrictions) until May 22, 2023. The PECO statement was created to clarify the research question, and articles that did not meet the criteria of this statement were excluded. In this review, animal studies, laboratory studies, books, review articles, conference papers and letters to the editors were avoided. Also, studies focused on the effect of air pollutants on cellular and biochemical changes (without investigating dementia) were also excluded. A quality assessment was done according to the type of design of each article, using the checklist developed by the Joanna Briggs Institute (JBI). Finally, selected studies were reviewed and discussed in terms of Alzheimer's dementia and non-Alzheimer's dementia. We identified 14,924 articles through a systematic search in databases, and after comprehensive reviews, 53 articles were found to be eligible for inclusion in the current systematic review. The results showed that chronic exposure to higher levels of air pollutants was associated with adverse effects on cognitive abilities and the presence of dementia. Studies strongly supported the negative effects of PM2.5 and then NO2 on the brain and the development of neurodegenerative disorders in old age. Because the onset of brain structural changes due to dementia begins decades before the onset of disease symptoms, and that exposure to air pollution is considered a modifiable risk factor, taking preventive measures to reduce air pollution and introducing behavioral interventions to reduce people's exposure to pollutants is advisable. more...
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.